Palladium-103 brachytherapy with continuous periodic intravitreal Anti-VEGF bevacizumab for ciliary body medulloepithelioma.

Wingate SL, Finger PT

Open source

DOI
10.1016/j.ajoc.2026.102692
Published
2026 Dec
Container
American journal of ophthalmology case reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ajoc.2026.102692,
  title = {Palladium-103 brachytherapy with continuous periodic intravitreal Anti-VEGF bevacizumab for ciliary body medulloepithelioma.},
  author = {Wingate SL and Finger PT},
  year = {2026},
  journal = {American journal of ophthalmology case reports},
  doi = {10.1016/j.ajoc.2026.102692},
  url = {https://doi.org/10.1016/j.ajoc.2026.102692}
}

RIS

TY  - JOUR
TI  - Palladium-103 brachytherapy with continuous periodic intravitreal Anti-VEGF bevacizumab for ciliary body medulloepithelioma.
AU  - Wingate SL
AU  - Finger PT
PY  - 2026
JO  - American journal of ophthalmology case reports
DO  - 10.1016/j.ajoc.2026.102692
UR  - https://doi.org/10.1016/j.ajoc.2026.102692
ER  - 

APA

SL, W., & PT, F. (2026). Palladium-103 brachytherapy with continuous periodic intravitreal Anti-VEGF bevacizumab for ciliary body medulloepithelioma.. American journal of ophthalmology case reports. https://doi.org/10.1016/j.ajoc.2026.102692

Source records